Abbvie Inc. Nyse: abbv The shares increased by approximately 2 % in the middle of the day after submitting the profit report in the second quarter of 2025. The Giant Giant Giant World, $ 15.42 billion, overcame the expectations of $ 14.93 billion. The summary was also a victory with the company that reported the $ 2.97 EPS, which was 2 % higher than $ 2.91.
Fear today
- 52 weeks
- 163.81 dollars
▼
218.66 dollars
- Profit
- 3.36 %
- P/E ratio.
- 83.41
- The target price
- 211.29 dollars
Investing in biotechnology stocks is often an option between stagnant arrows with large fish and small and small companies. Abbvie stands out that it is really one of the names of blue chips in the sector and the broader market.
The current ABBVIE portfolio helps to constantly increase revenues and profits. In addition, the company has a large -scale pipeline that maintains it at the forefront of industry.
ABBVIE is also a mainly strong company with a rock public budget that supports its position as the profit king. The company has Her profits have increased for 53 years in a rowThis profit is currently returning by 3.39 %.
Abbvie has successfully carried out humira needles
Over the past 18 months, investors have been very concerned about the end of the patent patents. During this transition, the ABBVIE administration was sure that its new drugs, Skyrizi and Rinvoq would pick up the recession.
this Net revenues in the world Cement results that idea for investors. Hemira’s net net revenues of $ 1.18 billion decreased by $ 58.1 % on an annual basis (YOY). However, the net Skyrizi revenues amounted to $ 4.42 billion, which was 61.8 % higher than YY, and Rinvoq made clear revenues of $ 2.02 billion, an increase of 41.8 %.
The company’s total immunity portfolio achieved $ 7.63 billion in global net revenues, approximately 50 % of its total semester of $ 15.42 billion, which was 6.8 % higher.
On the strength of these numbers, ABBVIE raised its EPS guidelines per year to a range of $ 11.88 and $ 12.08. Both depression and the highest party higher than the previous directives of the company from $ 11.67 to $ 11.87.
Company The upcoming expectations Especially impressive since it came after the United States announced a framework for a trade agreement with the European Union. Under the current framework, all the drugs produced by the European Union that enter the United States are subject to a 15 % tariff. This will affect Abbvie, whose treatment is made of wrinkles in Ireland.
What is the following for ABBVIE?
ABBVIE stock forecast today
211.29 dollars
8.80 % upModerate purchase
Based on 27 analyst classifications
| The current price | 194.20 dollars |
|---|---|
| High expectations | $ 250.00 |
| Average expectations | 211.29 dollars |
| Low expectations | 180.00 dollars |
ABBVIE shares details details
The drug wallet in ABBVIE is a strong reason for its stock. However, the company takes steps to show how it plans to add the value of the shareholders. One of these moves was announced in June: The company’s acquisition of Capstan Therapeutics of $ 2.1 billion.
This is a clinical stage, so it will not immediately add to the upper line. But it is another addition to the immune pipeline in Apfi. It provides more shots on ABBVIE, which has a strong history in obtaining drugs from clinical experiences and in the market.
In continuing growth through the subject of acquisition, ABBIE stated that he is talking to Gilgamesh Pharmaceuticals. This is the other vital technology in the clinical stage that focuses on narcotic drugs from the next generation.
The value of the deal is expected to be estimated at about one billion dollars. The importance is that the drug is a controversial field that would come close to credibility when supported in the name of the blue chip like ABBVIE.
ABBV: Grinding higher with eyes on the key 195 – 200 dollars resistance
Slow and fixed was the theme of ABBV, which was grinding higher than its lowest level in the fixed size. All eyes will range between $ 195 and $ 200, which has been resistance in the past few months.
Investors may be encouraged by moving the arrow above the simple moving average for 50 days (SMA).
The penetration will be almost certain if the analysts are behind a rally. ABBV shares are currently traded slightly less than the purpose of the consensus price. However, these The price goals are likely to move up After printing solid.
Before you think about Abbvie, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts whispered quietly to their customers to buy now before wiping the broader market … and ABBIE was not in the list.
While ABBIEE currently has a moderate purchase classification between analysts, analysts from the top rankings believe that these five stocks buy better.
Show the five stocks here
Do you look forward to profit from the huge direction of the electric car? Enter your email address and we will send you our list that shows EV shares for long -term capabilities.
